Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: Relation to clinical and hemodynamic responses

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 12, 2010, Pages 1283-1289

  Karavolias, George K ^a   Georgiadou, Panagiota ^a   Gkouziouta, Angeliki ^a   Kariofillis, Panagiotis ^a   Karabela, Georgia ^a   Tsiapras, Dimitrios ^a   Sbarouni, Eftihia ^a   Chaidaroglou, Antigoni ^a   Degiannis, Dimitrios ^a   Adamopoulos, Stamatis ^a   Voudris, Vassilis ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

bosentan; inflammatory markers; pulmonary arterial hypertension

Indexed keywords

BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CELL ADHESION MOLECULE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HEART OUTPUT; HEMODYNAMIC PARAMETERS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PULMONARY HYPERTENSION; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; ENDOTHELIN-1; EPOPROSTENOL; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; MIDDLE AGED; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 78249286243     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.523421     Document Type: Article

References (27)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94
3. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9
4. Giaid A, Yanagisawa M, Langeleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9 (Pubitemid 23170122)
5. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S (Pubitemid 38759713)
6. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheumatol 2009;36:760-7 • This paper reports on the effects of bosentan on endothelial markers in patients with pulmonary hypertension of a specific etiology.
7. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104:236-44
8. Kimura H, Okada O, Tanabe N, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001;164:319-24
9. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:1211-18
10. Giannelli G, Iannone F, Marinosci F, et al. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 2005;21:327-32
11. Giannelli G, Iannone F, Marinosci F, et al. Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. Eur J Clin Invest 2006;36:73-7
12. Davie N, Haleen SJ, Upton PD, et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405 (Pubitemid 34118516)
13. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31
14. Saleh D, Furukawa K, Tsao MS, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-93
15. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70 (Pubitemid 38296473)
16. Crapo RO, Casaburi R, Coates AL, et al. ATS statement: guidelines for six-minutes walk test. Am J Respir Crit Care Med 2002;166:111-7
17. Galie N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100 • This is the first study, to our knowledge, of bosentan therapy in patients with mildly symptomatic pulmonary arterial hypertension.
18. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8
19. Stratton RJ, Coghlan JG, Pearson JD, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998;91:561-6
20. Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008;67:1121-6 • This was the first paper, to our knowledge, reporting on the anti-inflammatory properties of bosentan in patients with pulmonary arterial hypertension.
21. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-31
22. Nishimaki T, Aotsuka S, Kondo H, et al. Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 1999;26:2357-62
23. Knobloch J, Peters H, Jungck D, et al. TNFalpha-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. Thorax 2009;64:1044-52
24. Gurbanov E, Shiliang X. The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur J Cardiothorac Surg 2006;30:499-507
25. Reesink HJ, Tulevski II, Marcus JT, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84:537-43
26. Magga J, Vuolteenaho O, Marttila M, Ruskoaho H. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ETA/ETB and AT1 receptor antagonists in vivo and in vitro. Circulation 1997;96:3053-62
27. Taniguchi T, Koido Y, Aiboshi J, et al. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999;27:1262-4